Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03128281
Other study ID # 2015-0973
Secondary ID NCI-2018-01330
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date July 2018
Est. completion date July 2022

Study information

Verified date May 2019
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to compare the level of pain 2 hours after surgery in patients after the use of the AirSeal® Insufflation System (AIS) at a high or low pressure setting or the standard insufflator (the conventional insufflation system, or CIS). "Insufflation" is the creation of a pressure barrier of air/gas within the abdomen that allows the surgeon more space to work in.


Description:

Baseline Visit:

If participant agrees to take part in this study, within 30 days before surgery, participant will be asked to complete a questionnaire about participant's pain level and any drugs participant may be taking for it. It should take about 5 minutes to complete.

Study Groups:

Participant will be randomly assigned to 1 of 3 groups (as in a roll of dice). This is done because no one knows if one study group is better, the same, or worse than the other group. Participant has an equal chance of being placed in each group. Participant will not know which group participant is assigned to.

- If participant is in Group 1, participant will have the CIS used during surgery.

- If participant is in Group 2, participant will have the AIS used at a lower pressure during surgery.

- If participant is in Group 3, participant will have the AIS used at a higher pressure during surgery.

Surgery:

Participant will then have surgery. Participant will sign a separate consent for the surgery that explains the procedure, the risks of the surgery, and the risks of CIS.

Blood (about 3 teaspoons each time) will be collected 1 time before surgery, 2 times during surgery, and 1 time after surgery is completed. Routine tests and tests to learn how participant's body reacts to inflammation will be performed on this blood.

Questionnaires:

After surgery, participant will complete the questionnaire about participant's pain level and any drugs participant is taking. Participant will complete this questionnaire:

- Two (2) hours after surgery,

- When participant leaves the post-anesthesia care unit (PACU), and

- When participant is discharged from the hospital

If participant is discharged the same day as participant's surgery, participant will be called by the study staff to answer the questionnaire the following day.

Length of Study Participation:

Participation in the study will be over after participant completes the questionnaire after participant is discharged, unless participant agrees to complete additional optional questionnaires.

This is an investigational study. Both AirSealĀ® insufflation system (AIS) and conventional insufflation systems (CIS) are FDA approved and commercially available. It is investigational to compare the effects of high and low pressures using the AIS.

Up to 240 participants will be enrolled in this study. All will take part at MD Anderson.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2022
Est. primary completion date July 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. All gynecologic laparoscopic/robotic surgeries EXCEPT diagnostic laparoscopies

2. 18-80 years of age

3. Capable and willing to provide Informed consent

4. Acceptable candidate for laparoscopic/robotic GYN surgery as per discretion of the surgeon

5. If patient agrees to participate in the optional patient reported outcomes portion of the study, patient must be English speaking and willing to complete the MD Anderson Symptom Inventory (MDASI) questionnaires

Exclusion Criteria:

1. Active cutaneous infection or inflammation

2. Pre-existing active or untreated immunodeficiency disorder and/or chronic use of systemic steroids

3. Uncontrolled diabetes mellitus

4. Severe co-existing morbidities having a life expectancy of less than 30 days

5. Significant anemia with hemoglobin level less than 7 g/dL or a hematocrit less than 21%

6. Females who are pregnant or lactating

7. Patients presenting with ascites

8. Patients with Chronic Pain Syndrome or requiring/using chronic pain medications

9. Patients undergoing diagnostic laparoscopy

10. Patients planning to undergo hand-assisted laparoscopy

11. Severe comorbidities (atrial fibrillation, pulmonary hypertension, etc...)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaires
Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge. Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete.
Device:
Conventional Insufflation System (CIS)
CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
ConMed AirSeal Insufflation System (AIS) at Low Pressure
AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
ConMed AirSeal Insufflation System (AIS) at Higher Pressure
AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center ConMed Corporation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery Incidence of shoulder pain defined by a positive (>0) score for an 11-point pain intensity numeric rating scale (PI-NRS). Post-operative day 1
See also
  Status Clinical Trial Phase
Withdrawn NCT02812056 - Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Phase 1
Active, not recruiting NCT02714439 - Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley Early Phase 1
Active, not recruiting NCT02774759 - Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers N/A
Recruiting NCT03093909 - Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Phase 1
Completed NCT03210376 - Neuromuscular Blockade on Shoulder Pain of Elderly Phase 4
Recruiting NCT02884648 - Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery Phase 2
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Withdrawn NCT02915172 - Lenvatinib and Capecitabine in Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT03162627 - Selumetinib and Olaparib in Solid Tumors Phase 1
Terminated NCT02740114 - Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway Phase 3
Active, not recruiting NCT03531645 - Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma Phase 2